Dow Down0.78% Nasdaq Down1.13%

Cepheid (CPHD)

-NasdaqGS
27.32 Down 1.13(3.97%) 4:00PM EDT
|After Hours : 27.32 0.00 (0.00%) 4:18PM EDT
ProfileGet Profile for:
Cepheid
904 Caribbean Drive
Sunnyvale, CA 94089
United States - Map
Phone: 408-541-4191
Fax: 408-541-4192
Website: http://www.cepheid.com

Details 
Index Membership:N/A
Sector:Technology
Industry:Scientific & Technical Instruments
Full Time Employees:1,700

Business Summary 

Cepheid, a molecular diagnostics company, develops, manufactures, and markets integrated systems for testing in the clinical and non-clinical markets. Its systems enable molecular testing for organisms and genetic-based diseases by automating manual laboratory procedures. The company primarily offers GeneXpert system that integrates sample preparation in addition to DNA amplification and detection. The GeneXpert system is designed for reference laboratories, hospital central laboratories, and satellite testing locations, such as emergency departments and intensive care units within hospitals, as well as physician offices and other alternate site laboratories. The company offers GeneXpert system for testing in the areas of healthcare-associated infections, critical infectious disease, sexual health, virology, oncology, and genetics. It also provides SmartCycler system, which integrates DNA amplification and detection to allow analysis of a sample; and Xpert tests for use on the GeneXpert system. The company sells its products through its direct sales force and distributors worldwide. It has collaboration arrangements with Life Technologies Corporation to develop reagents for use in the USPS BDS program; Foundation for Innovative New Diagnostics to develop tests that can detect mycobacterium tuberculosis and associated rifampin resistance from human sputum samples; and Paul G. Allen Family Foundation and the Bill & Melinda Gates Foundation to develop Xpert Ebola, an Ebola test to be run on its GeneXpert Systems. The company was incorporated in 1996 and is headquartered in Sunnyvale, California.

Key Statistics


Company Websites 
Home Page
Investor Relations
Search Yahoo! for:
More on Cepheid

Corporate Governance 
Cepheid’s ISS Governance QuickScore as of May 1, 2016 is 3. The pillar scores are Audit: 1; Board: 4; Shareholder Rights: 2; Compensation: 7.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
 PayExercised
Mr. John L. Bishop , 71
Chairman, Chief Exec. Officer and Member of Equity Incentive Committee
1.34M4.54M
Mr. Warren C. Kocmond Jr., 56
Pres and Chief Operating Officer
671.00K302.00K
Mr. Thomas L. Gutshall , 78
Co-Founder and Director
N/AN/A
Mr. Daniel E. Madden CPA, 48
Chief Financial Officer and Exec. VP
489.00K0.00
Dr. David H. Persing M.D., Ph.D., 60
Chief Medical & Technology Officer, Exec. VP, Director and Member of Equity Incentive Committee
680.00K749.00K
Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders